283
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude

, , , , &
Pages 75-85 | Received 18 Oct 2022, Accepted 22 Dec 2022, Published online: 15 Jan 2023

References

  • Leaf DE, Goldfarb DS. Mechanisms of action of Acetazolamide in the prophylaxis and treatment of acute mountain sickness. J Appl Physiol. 2007;102(4):1313–1322. doi:10.1152/japplphysiol.01572.2005
  • Dhillon S. Roxadustat: first Global Approval. Drugs. 2019;79(5):563–572. doi:10.1007/s40265-019-01077-1
  • Haase VH. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial Int. 2017;21(Suppl1):S110–s124. doi:10.1111/hdi.12567
  • Long G, Chen H, Wu M, et al. Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways. Front Pharmacol. 2020;11:1191. doi:10.3389/fphar.2020.01191
  • Deguchi H, Ikeda M, Ide T, et al. Roxadustat markedly reduces myocardial ischemia reperfusion injury in mice. Circ J. 2020;84(6):1028–1033. doi:10.1253/circj.CJ-19-1039
  • Wang B, Zhang YB, Zhang F, et al. On the origin of Tibetans and their genetic basis in adapting high-altitude environments. PLoS One. 2011;6(2):e17002. doi:10.1371/journal.pone.0017002
  • Mima A. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets. J Diabetes Res. 2013;2013:248563. doi:10.1155/2013/248563
  • Mima A, Yasuzawa T, King GL, Ueshima S. Obesity-associated glomerular inflammation increases albuminuria without renal histological changes. FEBS Open Bio. 2018;8:664–670. doi:10.1002/2211-5463.12400
  • Miao M, Wu M, Li Y, et al. Clinical potential of hypoxia inducible factors prolyl hydroxylase inhibitors in treating nonanemic diseases. Front Pharmacol. 2022;13:837249. doi:10.3389/fphar.2022.837249
  • Kirschner KM, Kelterborn S, Stehr H, et al. Adaptation of the oxygen sensing system during lung development. Oxid Med Cell Longev. 2022;2022:9714669. doi:10.1155/2022/9714669
  • Yasuoka Y, Izumi Y, Fukuyama T, et al. Effects of roxadustat on erythropoietin production in the rat body. Molecules. 2022;27(3):1119. doi:10.3390/molecules27031119
  • Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393–402. doi:10.1016/j.molcel.2008.04.009
  • Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A. 2006;103(48):18154–18159. doi:10.1073/pnas.0602235103
  • Bowser JL, Lee JW, Yuan X, Eltzschig HK. The hypoxia-adenosine link during inflammation. J Appl Physiol. 2017;123(5):1303–1320. doi:10.1152/japplphysiol.00101.2017
  • Eltzschig HK, Weissmüller T, Mager A, Eckle T. Nucleotide metabolism and cell-cell interactions. Methods Mol Biol. 2006;341:73–87. doi:10.1385/1-59745-113-4:73
  • Eltzschig HK. Extracellular adenosine signaling in molecular medicine. J Mol Med. 2013;91(2):141–146. doi:10.1007/s00109-013-0999-z
  • McIntosh VJ, Lasley RD. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant. J Cardiovasc Pharmacol Ther. 2012;17(1):21–33. doi:10.1177/1074248410396877
  • Koeppen M, Eckle T, Eltzschig HK. Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS One. 2009;4(8):e6784. doi:10.1371/journal.pone.0006784
  • Yang Z, Day YJ, Toufektsian MC, et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation. 2005;111(17):2190–2197. doi:10.1161/01.Cir.0000163586.62253.A5
  • Ge ZD, van der Hoeven D, Maas JE, Wan TC, Auchampach JA. A(3) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. J Mol Cell Cardiol. 2010;49(2):280–286. doi:10.1016/j.yjmcc.2010.01.018
  • Eltzschig HK, Bonney SK, Eckle T. Attenuating myocardial ischemia by targeting A2B adenosine receptors. Trends Mol Med. 2013;19(6):345–354. doi:10.1016/j.molmed.2013.02.005
  • Bowser JL, Phan LH, Eltzschig HK. The Hypoxia-Adenosine Link during Intestinal Inflammation. J Immunol. 2018;200(3):897–907. doi:10.4049/jimmunol.1701414
  • Eckle T, Hughes K, Ehrentraut H, et al. Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury. FASEB J. 2013;27(8):3078–3089. doi:10.1096/fj.13-228551
  • Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: advantages and disadvantages. Eur J Pharmacol. 2021;912:174583. doi:10.1016/j.ejphar.2021.174583